<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02266121</url>
  </required_header>
  <id_info>
    <org_study_id>B039201421534</org_study_id>
    <nct_id>NCT02266121</nct_id>
  </id_info>
  <brief_title>Improving Cognitive Aptitudes With tDCS in Patients With Multiple Sclerosis</brief_title>
  <acronym>MScog-tDCS</acronym>
  <official_title>Improving Cognitive Aptitudes With tDCS in Patients With Multiple Sclerosis / Améliorer Les capacités Cognitives Par tDCS Chez Les Patients Souffrants de sclérose en Plaques</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital of Mont-Godinne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Université Catholique de Louvain</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Teva Pharmaceuticals USA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital of Mont-Godinne</source>
  <brief_summary>
    <textblock>
      Noninvasive brain stimulations (NIBS) will be used in MS patients with cognitive impairments&#xD;
      to enhance their cognitive aptitudes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      tDCS will be used in a sham-controlled, double-blind, randomized, cross-over control trial in&#xD;
      MS patients suffering from cognitive impairments and/or motor deficits. After informed&#xD;
      consent and recruitment, patients will be randomly (computer method) allocated to real or&#xD;
      sham tDCS, that will be applied during working memory and attentional tasks. A few days/weeks&#xD;
      after completing one arm, the patients will enter the other arm (double-blind cross-over&#xD;
      design).&#xD;
&#xD;
      Baseline and follow-up outcomes about cognitive aptitudes, motor tasks and fatigue will be&#xD;
      collected.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    lack of recruitement&#xD;
  </why_stopped>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Enhancement of Cognitive aptitudes with tDCS</measure>
    <time_frame>from baseline to 4 weeks after the intervention</time_frame>
    <description>The effect of intervention on attentional, working memory and executive function deficits will be quantified by means of validated tests before and after intervention.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Enhancement of Motor skills with tDCS</measure>
    <time_frame>from baseline to 4 weeks after the intervention</time_frame>
    <description>Performance on motor skill learning tasks and on different commonly used tasks (Purdue Pegboard, hand dynamometer, pinch dynamometer, 9-HPT, motor skill learning with a videogame, ...) will be measured to explore the impact of tDCS on these parameters in MS patients' population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact on Fatigue and Enhancement of Cognitive performances with tDCS</measure>
    <time_frame>from baseline to 4 weeks after the intervention</time_frame>
    <description>The effect of intervention on fatigue and performances on the cognitive tasks will be quantified by means of validated questionnaires at inclusion and after tDCS.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Relapsing Remitting Multiple Sclerosis</condition>
  <condition>Secondary-progressive Multiple Sclerosis</condition>
  <condition>Cognitive Deficits</condition>
  <condition>Motor Deficits</condition>
  <arm_group>
    <arm_group_label>real tDCS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive non-invasive and painless brain stimulation over the rain areas involved in cognitive aptitudes.&#xD;
tDCS will be applied during 20 minutes while patients will perform attentional, working memory and executive tasks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham tDCS</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>this will be exactly as for &quot;real tDCS&quot; unless that the tDCS will be rapidly turned off, unbeknown from patients-therapist-examinator (double-blind trial)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>tDCS</intervention_name>
    <description>Device: transcranial direct current stimulation tDCS tdcs (ELDITH, Neuroconn, Ilmenau, Germany)</description>
    <arm_group_label>Sham tDCS</arm_group_label>
    <arm_group_label>real tDCS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  MS patients with relapsing remitting MS/secondary progression MS (based on the 2010&#xD;
             revised McDonald criteria)&#xD;
&#xD;
          -  Cognitive deficits&#xD;
&#xD;
          -  Motor deficits&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  contraindication to tDCS (seizure or epilepsy, metal in the head, …)&#xD;
&#xD;
          -  major psychiatric conditions or major depression&#xD;
&#xD;
          -  coexisting instable medical condition&#xD;
&#xD;
          -  substance or alcohol abuse&#xD;
&#xD;
          -  regular intake of drug that strongly modulate brain excitability&#xD;
&#xD;
          -  major sequels from MS preventing participation in the study&#xD;
&#xD;
          -  pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Neurology, CHU Dinant Godinne UcL Namur</name>
      <address>
        <city>Yvoir</city>
        <state>Namur</state>
        <zip>B-5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>October 10, 2014</study_first_submitted>
  <study_first_submitted_qc>October 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2014</study_first_posted>
  <last_update_submitted>April 28, 2021</last_update_submitted>
  <last_update_submitted_qc>April 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital of Mont-Godinne</investigator_affiliation>
    <investigator_full_name>Pr Yves Vandermeeren, MD, PhD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>MS</keyword>
  <keyword>Cognitive deficits</keyword>
  <keyword>Motor deficits</keyword>
  <keyword>Fatigue</keyword>
  <keyword>Nervous System Diseases</keyword>
  <keyword>Brain Diseases</keyword>
  <keyword>Brain stimulation</keyword>
  <keyword>Working memory</keyword>
  <keyword>Motor learning</keyword>
  <keyword>Central Nervous System Diseases</keyword>
  <keyword>Neuropsychological rehabilitation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
    <mesh_term>Multiple Sclerosis, Chronic Progressive</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Cognition Disorders</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

